Immunology

Making immunotherapy safe for AML

Acute myeloid leukemia (AML), the second most common leukemia in children, is hard to treat and has a five-year survival rate of just 65 to 70%, according to the American Cancer Society. While immunotherapies like monoclonal ...

Oncology & Cancer

Two antibodies synergize in triple whammy to pediatric cancers

A combination of anti-cancer antibodies produced a powerfully synergistic response in two hard-to-treat pediatric cancers, according to a new study, in mice, led by researchers at the Stanford University School of Medicine.

Oncology & Cancer

Mineralization of bone matrix regulates tumor cell growth

Tumor cells are known to be fickle sleeper agents, often lying dormant in distant tissues for years before reactivating and forming metastasis. Numerous factors have been studied to understand why the activation occurs, from ...

page 13 from 40